Theraclone Sciences (fka: Spaltudaq) is focused on developing novel therapeutic antibodies for use in cancer, infectious disease and auto-immune disease settings. The company portfolio's technology platform, harnesses the specificity and repertoire of the human immune system to identify and produce fully human monoclonal antibodies. Significantly, Theraclone's process is very rapid, leading to the identification and testing of fully human antibodies within a few weeks of the initial sample analysis. The speed and simplicity of this approach allows multiple candidate antibodies to be evaluated in a short period of time and enables selection of those antibodies with the greatest therapeutic potential for further development efforts.

Portfolio Home